Stockscreener 앱 받기
180.98
2.67%
4.71
시장 영업 전:
181.00
0.02
+0.01%
전일 마감가:
$176.27
열려 있는:
$174.17
하루 거래량:
787.62K
Relative Volume:
0.70
시가총액:
$10.21B
수익:
$763.34M
순이익/손실:
$51.40M
주가수익비율:
199.23
EPS:
0.9084
순현금흐름:
$104.46M
1주 성능:
-0.35%
1개월 성능:
+28.35%
6개월 성능:
+40.59%
1년 성능:
+47.96%
1일 변동 폭
$174.01
$181.07
1주일 범위
$174.01
$185.34
52주 변동 폭
$100.99
$188.73
Repligen Corp Stock (RGEN) Company Profile
명칭
Repligen Corp
전화
(781) 449-9560
주소
41 SEYON STREET, WALTHAM, MA
Compare RGEN vs ISRG, BDX, ALC, RMD, MDLN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RGEN
Repligen Corp
|
180.98 | 10.17B | 763.34M | 51.40M | 104.46M | 0.9084 |
ISRG
Intuitive Surgical Inc
|
376.86 | 132.30B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
188.11 | 51.11B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
72.06 | 35.25B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
240.10 | 32.95B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.03 | 28.58B | 29.14B | 1.07B | 1.05B | 1.1956 |
Repligen Corp Stock (RGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-10-01 | 개시 | HSBC Securities | Buy |
| 2025-09-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-07-22 | 재개 | Stephens | Overweight |
| 2025-06-24 | 개시 | Barclays | Overweight |
| 2025-04-29 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 개시 | Evercore ISI | In-line |
| 2025-02-10 | 개시 | TD Cowen | Buy |
| 2024-12-17 | 개시 | Canaccord Genuity | Hold |
| 2024-11-14 | 개시 | Wolfe Research | Peer Perform |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-26 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2024-06-18 | 개시 | Guggenheim | Neutral |
| 2023-12-04 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-07-20 | 개시 | Wells Fargo | Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-03-28 | 개시 | The Benchmark Company | Buy |
| 2022-12-14 | 개시 | Deutsche Bank | Hold |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-07-20 | 개시 | UBS | Buy |
| 2021-10-14 | 개시 | Exane BNP Paribas | Outperform |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-08-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-07 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-11-01 | 업그레이드 | First Analysis Sec | Outperform → Strong Buy |
| 2019-10-15 | 개시 | SVB Leerink | Outperform |
| 2019-08-28 | 재확인 | First Analysis Sec | Outperform |
| 2019-08-23 | 재개 | Stephens | Overweight |
| 2019-07-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2018-12-17 | 업그레이드 | CL King | Neutral → Buy |
| 2018-11-12 | 다운그레이드 | CL King | Buy → Neutral |
| 2018-09-26 | 개시 | H.C. Wainwright | Neutral |
| 2017-12-08 | 개시 | Citigroup | Buy |
| 2017-12-05 | 개시 | JP Morgan | Overweight |
| 2017-11-13 | 개시 | CL King | Buy |
| 2017-10-02 | 업그레이드 | First Analysis Sec | Equal-Weight → Overweight |
| 2017-07-21 | 개시 | William Blair | Outperform |
| 2017-02-13 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
모두보기
Repligen Corp 주식(RGEN)의 최신 뉴스
Repligen Corp (RGEN) CEO Olivier Loeillot Sells 5,426 Shares - GuruFocus
Repligen (NASDAQ: RGEN) CEO trades shares at $180 under 10b5-1 plan - Stock Titan
LVIP Baron Growth Opportunities Fund's Repligen Corp(RGEN) Holding History - GuruFocus
Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal - Quiver Quantitative
Repligen (NASDAQ: RGEN) plan covers 5,426-share sale after option exercise - Stock Titan
Repligen Corporation stock hits 52-week high at 176.52 USD By Investing.com - Investing.com South Africa
Repligen Corporation stock hits 52-week high at 176.52 USD - Investing.com
Oppenheimer Asset Management Inc. Purchases New Position in Repligen Corporation $RGEN - MarketBeat
Repligen Corp (RGEN) stake at 3.1% in new T. Rowe Price 13G/A - Stock Titan
Repligen Corporation (RGEN) Stock Forecasts - Yahoo! Finance Canada
Wasatch Advisors LP Buys 346,720 Shares of Repligen Corporation $RGEN - MarketBeat
Assenagon Asset Management S.A. Buys New Shares in Repligen Corporation $RGEN - MarketBeat
Repligen Corporation (RGEN) stock price, news, quote and history - Yahoo Finance UK
Repligen Corporation (NASDAQ:RGEN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Repligen (RGEN) Is Up 16.2% After Revenue Rises But Profitability Compresses In Q2 2026 - Yahoo Finance
Repligen Corp (RGEN) Stock News Today - TradingKey
Repligen Corp (RGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
The Manufacturers Life Insurance Company Decreases Holdings in Repligen Corporation $RGEN - MarketBeat
Is It Too Late to Buy Repligen Corp (RGEN) After 5.8% Rally? GF Value Says Undervalued - GuruFocus
Moody National Bank Trust Division Makes New Investment in Repligen Corporation $RGEN - MarketBeat
California State Teachers Retirement System Raises Holdings in Repligen Corporation $RGEN - MarketBeat
Repligen Submits Form 425 Detailing Proposed Acquisition of BioLife Solutions - Kalkine Media
Repligen Corp (RGEN) Stock Up 4.3% and Still Undervalued -- GF S - GuruFocus
Repligen Earnings: Excellent Profit Margins, China Recovery Underway - Morningstar
Repligen Corporation $RGEN Shares Acquired by Avidity Partners Management LP - MarketBeat
Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G - Stock Titan
Repligen Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade - Yahoo Finance
Repligen Beats Q2 Earnings Estimates, Raises 2026 View, Stock Up - Barchart.com
Canaccord reiterates Hold on Repligen stock, keeps $145 target By Investing.com - Investing.com Nigeria
Repligen Offers Differentiated Solutions as a Leading Bioprocessing Supplier - Morningstar
Repligen Corp (RGEN) Shares Surge 11.0% -- What GF Score of 87 T - GuruFocus
Repligen Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Repligen Corp (RGEN) Q2 2026 Earnings Call Transcript - AlphaStreet
Is Repligen Corp (RGEN) Undervalued After Q2 Earnings Beat? EPS - GuruFocus
Repligen raises FY2026 adj EPS guidance to $2.03-$2.09 - scanx.trade
Repligen Reports Q2 2026: Revenue $204M, Adjusted EPS $0.54; Raises FY26 Guidance - TradingView
Repligen Q2 2026 revenue rises 12% to $204 million - Quiver Quantitative
Repligen Reports Q2 2026 Revenue Growth, Raises Full-Year Organic Revenue and EPS Guidance - Quiver Quantitative
Repligen: Q2 Earnings Snapshot - Yahoo Finance
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance - Yahoo Finance
Repligen Corp (RGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Repligen Corp (RGEN) Balance Sheet - TradingKey
Repligen Corp (RGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Repligen earnings in focus after $1.5B BioLife acquisition By Investing.com - Investing.com South Africa
Repligen Corp (RGEN) Institutional Confidence - TradingKey
RGEN|Repligen Corp|Price:131.960|Chg%:-5.640 - TradingKey
Repligen Corp (RGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Repligen (RGEN) Q2 Earnings: What To Expect - Yahoo! Finance Canada
Repligen Corp (RGEN) Cash Flow - TradingKey
ETFs Investing in Repligen Corporation Stocks - TradingView
Repligen Corp (RGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Repligen Corp 주식 (RGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer |
Aug 20 '26 |
Sale |
180.00 |
5,426 |
976,680 |
54,246 |
1.40%
0.50%
자본화:
|
볼륨(24시간):